Combination therapy stops loss of kidney function in rare genetic disease

---

Omschrijving
A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, Mass.) -- is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.

 

[ Ga naar het volledige artikel toe ]

Categorie: nieren

[Reinig uw lichaam met de Chlorella alg - 100% plantaardig ]

Het hoofdmenu
Nieuws
Supervoeding
Zoek op onderwerp